Furthermore, the pharmacological inhibition of two target proteins, together with BCR-ABL1, using IM + difluorinated curcumin (DFC) + (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI) induced both elimination of CML stem and progenitor cells assayed in LTC-IC while sparing normal CD34+. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.